Halle, Germany-based Probiodrug has appointed Mark Booth as its chief business officer and member of its management board.
Booth joins the Alzheimer’s disease specialty biopharmaceutical firm from Orexigen Therapeutics, where he served as chief commercial officer leading its business development and investor relations activities.
He brings over 30 years of biopharmaceutical experience to Probiodrug and has held key positions at Abbott Laboratories, Immunex Corporation and Takeda Pharmaceuticals, where he served as president of its North America operations.
Dr Erich Platzer, chairman of Probiodrug’s supervisory board, said: “Mark’s broad business background and proven track record make him a valuable addition to our management board.
“His extensive experience in business development and investor relations will be instrumental to propel Probiodrug’s strategy internationally and in particular [in] the United States.”
Booth said: “This is truly a unique opportunity and I look forward to working with the team as we advance new and novel therapeutic treatments for Alzheimer’s patients.”